These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 638979)

  • 1. Adjuvant chemotherapy.
    Skipper HE
    Cancer; 1978 Mar; 41(3):936-40. PubMed ID: 638979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy: theoretical considerations and model studies.
    van Putten LM; de Ruiter J; van de Velde CJ; Mulder JH; Gerritsen AF
    Recent Results Cancer Res; 1979; 67():119-25. PubMed ID: 451320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical concepts derived from animal chemotherapy studies.
    Goldin A; Schabel FM
    Cancer Treat Rep; 1981; 65 Suppl 3():11-9. PubMed ID: 7049366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival.
    Begg AC; Fu KK; Kane LJ; Phillips TL
    Cancer Res; 1980 Jan; 40(1):145-54. PubMed ID: 7349894
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of surgery and pretreatment or posttreatment adjuvant chemotherapy on primary tumor growth in an animal model.
    Straus MJ; Sege V; Choi SC
    J Surg Oncol; 1975; 7(6):497-512. PubMed ID: 1186267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer chemotherapy: drug combination and multiple modality treatment.
    Cain BF
    N Z Med J; 1976 Nov; 84(575):364-9. PubMed ID: 1071151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of tumor regrowth to tumor cell survival, tumor cure rates and host survival in a solid tumor model following combined chemotherapy and radiotherapy.
    Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED
    In Vivo; 1994; 8(1):97-105. PubMed ID: 8054518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model studies in adjuvant chemotherapy.
    Mulder JH; de Ruiter J; Edelstein MB; Gerritsen TF; van Putten LM
    Cancer Treat Rep; 1983 Jan; 67(1):45-50. PubMed ID: 6616492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences and similarities in adjuvant chemotherapy in mouse and man.
    van Putten LM; Gerritsen AF
    Cell Tissue Kinet; 1981 Jan; 14(1):103-10. PubMed ID: 7471153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy--clinical trials and laboratory models.
    Wittes RE
    Cancer Treat Rep; 1986 Jan; 70(1):87-103. PubMed ID: 3510738
    [No Abstract]   [Full Text] [Related]  

  • 12. The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer.
    DeVita VT
    Cancer; 1983 Apr; 51(7):1209-20. PubMed ID: 6825044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concepts for treatment of micrometastases developed in murine systems.
    Schabel FM
    AJR Am J Roentgenol; 1976 Mar; 126(3):500-11. PubMed ID: 178196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body burden of cancer in relationship to therapeutic outcome: consideration of preclinical evidence.
    Griswold DP
    Cancer Treat Rep; 1986 Jan; 70(1):81-6. PubMed ID: 3943116
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of multicellular resistance on the survival of solid tumors, including micrometastases.
    Kerbel RS
    Invasion Metastasis; 1994-1995; 14(1-6):50-60. PubMed ID: 7657532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
    Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
    Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
    Feleszko W; Mlynarczuk I; Balkowiec-Iskra EZ; Czajka A; Switaj T; Stoklosa T; Giermasz A; Jakóbisiak M
    Clin Cancer Res; 2000 May; 6(5):2044-52. PubMed ID: 10815931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal timing of adjuvant chemotherapy in mouse models.
    van Putten LM
    Prog Clin Biol Res; 1985; 201():15-21. PubMed ID: 3867900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.